anti-Saccharomyces Cerevisiae Antibodies In Patients Research Articles

Anti-Saccharomyces cerevisiae Antibodies (ASCA) Researched by Tube Precipitins are Elevated in Patients with Dermatologic and Gastrointestinal Non-Ige-Mediated Hypersensitivity

Background: The presence of anti-Saccharomyces cerevisiae antibodies (ASCA) has been reported in the serum of patients with several immune-inflammatory diseases. Objective: To evaluate the presence of ASCA in patients with non-IgE-mediated hypersensitivity. Methods: A group of 222 patients with non-IgE-mediated hypersensitivity was divided into three groups according to dermatologic, gastrointestinal, and respiratory symptoms. Group D was composed of 163 patients with dermatologic symptoms diagnosed as intrinsic atopic dermatitis and/or non-IgE-mediated urticaria. Group G was composed of 23 patients diagnosed with non-IgE-mediated gastrointestinal food allergies. Group R was composed of 36 patients with respiratory symptoms diagnosed as non-IgE-mediated rhinitis and/or non-IgE-mediated asthma. Results: The Wilcoxon-Mann-Whitney U test comparing the precipitin’s titers of group G and group D showed a non-significant p-value of 0.83366. The Wilcoxon-Mann-Whitney U test comparing the precipitin’s titers of group R and group G showed a significant p-value of 0.00034. The Wilcoxon-Mann-Whitney U test comparing the precipitin’s titers of group R and group D showed a significant p-value < 0.0001. Conclusion: The patients with respiratory symptoms diagnosed as non-IgE-mediated rhinitis and/or asthma presented significantly less humoral immunoreactivity against S. cerevisiae than patients with non-IgE-mediated food allergy and patients with intrinsic atopic dermatitis and/or non-IgE-mediated urticaria. The elevation of ASCA titers may be an unspecific marker of intestinal hyperpermeability, and possibly may participate in Gell and Coomb’s types II and/or type III hypersensitivity reactions responsible for the patient’s dermatologic and gastrointestinal symptoms.

Anti-Saccharomyces cerevisiae antibodies in patients with COVID-19

Background and study aimAnti-Saccharomyces cerevisiae antibodies (ASCA) have been described in many autoimmune diseases (AIDs). Coronavirus disease 2019 (COVID-19) could trigger AIDs. This study aimed to determine the frequency of ASCA in patients with COVID-19. Patients and methodsThis study included 88 adult patients with severe COVID-19, 51 mild COVID-19, and 160 healthy blood donors. ASCA of isotype immunoglobulin (Ig)G and IgA were detected by enzyme-linked immunosorbent assay. ResultsThe frequency of ASCA (IgG or IgA) was significantly higher in patients with severe COVID-19 (21.6 % vs 3.7 %, p < 10−3) and in patients with mild COVID-19 than in the healthy controls (13.7 % vs 3.7 %, p = 0.03). ASCA-IgA was significantly more frequent in patients with severe COVID-19 than in healthy controls (15.9 % vs 0.6 %, p < 10−3). ASCA-IgG was significantly more frequent in patients with mild COVID-19 than in healthy controls (13.7 % vs 3.1 %, p = 0.02). ASCA (IgG or IgA) were more frequent in severe than in mild COVID-19, but the difference was not statistically significant (21.6 % vs 13.7 %). ASCA-IgA was significantly more frequent in patients with severe than those with mild COVID-19 (15.9 % vs 0 %, p = 0.003). The mean ASCA-IgG and ASCA-IgA levels were significantly higher in patients with severe COVID-19 than in healthy controls (5.8 U/mL ± 11.8 vs 2.3 U/mL ± 2.8, p < 10−3 and 9.2 U/mL ± 21.5 vs 3.4 U/mL ± 1.7, respectively, p < 10−3). The mean ASCA-IgG levels were significantly higher in patients with mild COVID-19 than in healthy controls (6.2 U/mL ± 12.9 vs 2.3 U/mL ± 2.8, p < 10−3). The mean ASCA-IgA levels were significantly higher in patients with severe than in those with mild COVID-19 (9.2 U/mL ± 21.5 vs 2.6 U/mL ± 1.2, p = 0.03). ConclusionASCA was more frequent in patients with COVID-19 than in healthy controls.

ELISA validation approach for the detection of anti-saccharomyces cerevisiae antibodies in patients treated with biopharmaceutical heberprot-P®

This work describes the validation of an enzyme-linked immunosorbent assay (ELISA) for detection of anti-Saccharomyces cerevisiae antibodies (ASCA) in diabetic patients with foot ulcers, after the treatment with Heberprot-P®. Validation followed regulatory guidelines of US FDA and European Medicine Agency. Minimum required dilution of samples and quality controls were defined using pools of sera from diabetic patients and from healthy donors. Parameters such as cut point, specificity, precision, selectivity, robustness and sample stability were analyzed. The repeatability and intermediate precision percent ranged between 7.93-10.61% and 7.93-11.43 %, respectively, indicating low intra- and inter-assay variation. The specificity was proved by background noise suppression, reaching 100% of inhibition as strong criterion for the specificity of the immunoassay. The validated ELISA is a reliable tool for ASCA detection in human serum after the administration of Heberprot-P®, in order to find immunological reactions associated with latent contamination by host cell proteins from Saccharomyces cerevisiae.

Anti-Saccharomyces cerevisiae IgG and IgA antibodies are associated with systemic inflammation and advanced disease in hidradenitis suppurativa

Anti-Saccharomyces cerevisiae IgG and IgA antibodies are associated with systemic inflammation and advanced disease in hidradenitis suppurativa

An investigation into the relationship between anti-Helicobacter pylori and anti-Saccharomyces cerevisiae antibodies in patients with axial spondyloarthritis and Crohn disease.

Spondyloarthritis (SpA) is a musculoskeletal inflammatory disease linked with immune responses to intestinal microbiota, and subclinical intestinal ulcerations that are closely related to inflammatory bowel diseases. Helicobacter pylori is a common cause of gastroduodenal ulceration, and anti-Saccharomyces cerevisiae antibodies (ASCA) are associated with intestinal inflammation in both Crohn disease (CD) and SpA. We investigated the relationship between H. pylori and ASCA. Ninety-one patients with axial SpA and forty with CD were included. ASCA IgG/IgA and anti-H. pylori IgG titers were assessed by ELISA. The proportion of ASCA+ patients in the positive and negative anti-H. pylori IgG groups with SpA and CD were compared using Chi-square tests, and correlations were evaluated using the Spearman's coefficient. Anti-H. pylori IgG titers were significantly negatively correlated with the ASCA IgG (r = -0.563, p < 0.001) and IgA (r = -0.342, p = 0.019) titers in the axial SpA patients. The same pattern of negative correlation was also observed in the CD patients. Anti-H. pylori+ serology was significantly more frequent in axial SpA patients than in those with CD (52.4 vs. 18.4 %, p < 0.001), while ASCA+ serology was significantly more frequent in CD patients than in SpA patients. A negative correlation between the anti-H. pylori titers and ASCA was found for axial SpA and CD. Anti-H. pylori+ serology was more frequent in SpA than in CD, while ASCA positivity was more frequent in CD patients than in those with SpA. A possible influence of H. pylori on the development of ASCA needs further investigation.

Anti-Saccharomyces cerevisiae Antibodies Are Elevated in Graves’ Disease But Not in Hashimoto’s Thyroiditis

Background. Anti-Saccharomyces cerevisiae antibodies (ASCA) had been known to be specific for Crohn’s disease, but they had also been found in many other autoimmune diseases. Aim. The aim of this study was to evaluate the prevalence of ASCA in patients with autoimmune thyroid disease (AITD). Patients and Methods. One hundred and ninety-seven patients with AITD and 160 healthy controls were included in the study. One hundred and nineteen patients had Graves’ disease (GD) and 78 patients had Hashimoto’s thyroiditis (HT). ASCA IgG and IgA were determined by ELISA. Results. ASCA IgG were significantly more frequent in patients with GD than in control group (11.8% vs. 3.1%, p = 0.002). In HT, the frequency of ASCA IgG was similar to that of the control group (3.8% and 3.1% respectively). The frequency of ASCA IgA was similar in GD (0.8%), HT (2.6%), and the control group (3.1%). In all GD patients, the frequency of ASCA IgG was significantly higher than that of ASCA IgA (11.8% vs. 0.8%, p = 0.001). These results were also true even in male and female groups (10.4% vs. 1.3%, p = 0.01 and 14.3% vs. 0%, p = 0.01, respectively). ASCA IgG levels were significantly higher in GD patients (6.7 ± 11.1 vs. 2.2 ± 2.8, p = 3 × 10−6) and in HT patients (4.2 ± 4.7 vs. 2.2 ± 2.8, p = 0.0002) than those in the control group. ASCA IgA levels were comparable among patients with GD, HT, and the control group. In GD patients, the mean titer of ASCA IgG was significantly higher than that of ASCA IgA (6.7 ± 11.1 vs. 3.6 ± 4.2, p = 0.005). Conclusion. Patients with GD had a higher frequency of ASCA IgG than controls.

Anti-Saccharomyces cerevisiae antibodies in patients with systemic lupus erythematosus

Anti-Saccharomyces cerevisiae antibodies (ASCA) had been known to be specific for Crohn's disease but it has been found in many other autoimmune diseases like systemic lupus erythematosus (SLE). Furthermore, cross-reactive epitopes on β2-glycoprotein I (β2GPI) and Saccharomyces cerevisiae were found in SLE patients. The aims of this study were to evaluate the frequency of ASCA in patients with SLE and to compare it with that of anti-β2GPI antibodies (aβ2GPI). Sera of 116 patients with SLE were analyzed in this retrospective study. All patients fulfilled at least 4 criteria of the 1997 American College of Rheumatology updated criteria for the classification of SLE. Sera of 160 blood donors were included as normal controls. ASCA IgA and IgG and aβ2GPI antibodies were determined by enzyme-linked immunosorbent assays. The frequency of ASCA (IgG and/or IgA) was significantly higher in SLE patients than in control group (31.9 vs. 3.7 %, p < 10(-6)). ASCA IgG and ASCA IgA were more frequent in SLE patients than in control group (29.3 vs. 3.1 %, p < 10(-6) and 12.1 vs. 0.6 %, p = 10(-4), respectively). The mean level of ASCA IgG was higher than that of ASCA IgA (9.5 vs. 6.4 U/ml) but the difference was not statistically significant. The frequencies of aβ2GPI (IgG and/or IgA) and aβ2GPI IgA were significantly higher than those of ASCA (IgG and/or IgA) and ASCA IgA (54.3 vs. 31.9 %, p = 5 × 10(-4) and 50.9 vs. 12.1 %, p < 10(-6), respectively). Increased ASCA IgG was observed in patients with SLE, suggesting a role of environmental stimuli in its pathogenesis.

The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China

Perinuclear anti-neutrophil cytoplasmic (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) have been studied extensively in Western countries. We determined the prevalence of pANCA and ASCA in the mainland Chinese population and the ability of pANCA and ASCA to discriminate between ulcerative colitis (UC) and Crohn's disease (CD). Two hundred-six unrelated patients with IBD (UC, n=152; CD, n=54), 60 patients with other gastrointestinal diseases, and 80 healthy controls were included. Sera pANCA and ASCA titers were determined by a standardized indirect immunofluorescence technique. The sensitivity, specificity, positive and negative predictive values, and positive likelihood ratio of pANCA were calculated for differentiating UC from healthy controls (43.4%, 96.3%, 95.7%, 47.2%, and 11.7, respectively) and ASCA for differentiating CD from healthy controls and (46.3%, 96.3%, 89.3%, 72.6%, and 12.5, respectively). The combination of pANCA and ASCA did not result in greater diagnostic efficiency than either test alone. pANCA was more frequent in UC with extensive or severe phenotype than others. ASCA was associated with severe CD disease activity. pANCA and ASCA are useful in confirming the diagnosis of IBD and differentiating between UC and CD in an IBD cohort in central China.

Clinical utility of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces Cerevisiae antibodies for discriminating specific intestinal inflammations

Background: The role of perinuclear antineutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) assessment in inflammatory bowel disease (IBD) diagnosis and differentiating is still imprecise and controversial. Methods: The aim of the study was to determine the accuracy of pANCA and ASCA in patients with specific intestinal inflammations, namely UC, CD, GI Behcet (GI-BD), GI tuberculosis (GI-TBC) which are under the same inflammatory bowel registry, compared to tree control groups; namely, Celiac disease, irritable bowel syndrome (IBS) patients and healthy controls (HC). A total of 493 subjects (102 with UC, 63 with CD, 13 with GI BD, 10 with GI Tb, 130 with IBS, 10 with Celiac disease, and 165 HC) firstly admitted to our weekly IBD outpatient practice of a tertiary referral center were analyzed regarding pANCA and ASCA Ig A-G via immunofluorescent assay (IFA) with commercially available IFA kits (Euroimmune, Lübeck, Germany). Results: The prevalence of any pANCA or ASCA positivity and age and sex of patients are summarized in Table 1. In UC patients the prevalence of pANCA was 42.2%, which was significantly higher than in CD-4.8% (p = 0.000). ASCA was found significantly more often in CD-54% than in UC patients-4.8% (p = 0.000). The prevalence of ASCA in BD patients-15.4% disclosed a significant difference compared to CD patients (p = 0.014), but the prevalence of ASCA in TBC patients showed no significant difference compared to CD or BD patients. Table 1: Prevalence of pANCA and ASCA in different subgroups.Marked values(p < .05)Tabled 1pANCA(+)ASCA(+)agemale(%)IBS (n = 130)1(0.8%)4(3.07%)40.84(SD 12.69)*42.3(a)HC (n = 165)1(0.6%)7(4.2%)35.07(SD 10.49)*;**40(b)UC (n = 102)43 (42.2%)11(10.8%)40.72(SD 13.44)**50(c)CD (n = 63)3 (4.8%)34(54%)37.56(SD 12.65)38.1(d)GI-BD (n = 13)02(15.4%)32.11(SD 8.89)61(e)Celiac Disease (n = 10)04(40%)36.77(SD 7.94)0(a;b;c;d;e;f)GI-TBC (n = 10)1(10%)3(30%)(SD 9.96)70(f) Open table in a new tab Conclusion: Our results confirm that in clinical practice ASCA is not specific enough to be a useful tool in differential diagnosis of any specific inflammation. However, it may have some value in screening of normal population for any bowel inflammation. pANCA may have a better clinical value in the discrimination of UC from other intestinal inflammations. Abstracts for SupplementInternational Journal of Infectious DiseasesVol. 14Preview Full-Text PDF Open Archive

Association between intestinal permeability and anti-Saccharomyces cerevisiae antibodies in patients with Crohnʼs disease

Association between intestinal permeability and anti-Saccharomyces cerevisiae antibodies in patients with Crohnʼs disease

Anti-Saccharomyces cerevisiae Antibodies in Patients with Inflammatory Bowel Disease and Their First-Degree Relatives: Potential Clinical Value

Anti-Saccharomyces cerevisiae antibodies (ASCA) have been described as specific markers in Crohn’s disease and their healthy first-degree relatives. 171 patients with Crohn’s disease, their 105 first-degree relatives, 145 patients with ulcerative colitis and 101 first-degree relatives of patients with ulcerative colitis, 50 patients with infectious enterocolitis and 100 healthy controls were tested for ASCA employing the ELISA technique. When compared with the healthy controls (p < 0.0001) and patients with infectious enterocolitis (p < 0.0001) the prevalence of ASCA was significantly increased in patients with Crohn’s disease and their first-degree relatives (p < 0.01). Further significant differences concerning the frequency of ASCA within the different groups of our study population were not observed. In particular, ASCA were not found in increased prevalence in infectious enterocolitis. These observations are compatible with a role of ASCA as a marker of genetic predisposition to Crohn’s disease.